Abstract:Background: Aberrant O-glycosylation of IgA1 plays an important role in IgA nephropathy pathogenesis. Previous proteomic studies analyzed O-glycans of the circulating IgA1 hinge region and found that the N-acetylgalactosamine (GalNAc) and galactose numbers in the hinge region of IgA1 of patients with IgA nephropathy were lower than those in healthy participants. However, the diagnostic performance of the O-glycosylation traits in the hinge region of plasma IgA1 for IgA nephropathy remains unelucidated. The present study aimed to determine the difference in plasma IgA1 hinge region O-glycoforms among IgA nephropathy, non-IgA nephropathy disease controls, and healthy participants, and to further evaluate the diagnostic performance of plasma IgA1 glycosylation traits. Methods: Sixty-two patients with biopsy-proven primary IgA nephropathy, 30 age- and sex-matched non-IgA nephropathy disease controls (10 patients with membranous nephropathy, 10 with focal segmental glomerulosclerosis, and 10 with minimal change disease), and 30 healthy participants were prospectively recruited. Plasma galactose deficient-IgA1 levels were measured using a KM55 kit. Plasma IgA was extracted using IgA immunoaffinity beads. After de-N-glycosylation, reduction, alkylation, trypsin digestion, and O-glycopeptide enrichment via hydrophilic interaction liquid chromatography, liquid chromatography tandem mass spectrometry (LC-MS/MS) was applied to analyze the IgA1 O-glycosylation patterns and we derived the plasma IgA1 O-glycosylation traits. Results: Plasma IgA1 O-glycosylation patterns were significantly changed in IgA nephropathy patients compared to those with non-IgA nephropathy disease controls and healthy participants. The GalNAc number was lowest in IgA nephropathy patients. In addition, a similar result was observed for the galactose number in the IgA1 hinge region. These values showed moderate potential for discriminating between IgA nephropathy and the controls. When these values were combined, the area under the curve increased compared to when they were considered individually. When further adding a clinical indicator, the area under the curve of the GalNAc-galactose-IgA panel exceed 0.9 in discriminating IgA nephropathy from the controls. Conclusion: The amount of GalNAc and galactose in plasma IgA1 hinge region identified by glycoproteomics could be used as a diagnostic biomarker for IgA nephropathy. The panel containing GalNAc, galactose, and circulating IgA displayed excellent diagnostic performance and is promising for practical clinical applications.

N-glycosylation of Serum Proteins for the Assessment of Patients with IgD Multiple Myeloma

Isomer-specific Biomarker Discovery in Multiple Myeloma with Dual-Derivatized N-glycans.

High-Throughput Profiling of Serological Immunoglobulin G N -Glycome as a Noninvasive Biomarker of Gastrointestinal Cancers

Site-specific N-glycosylation characterization of micro monoclonal immunoglobulins based on EThcD-sceHCD-MS/MS

Diagnostic Potential Of Plasma Igg N-Glycans In Discriminating Thyroid Cancer From Benign Thyroid Nodules And Healthy Controls

Causal link between immunoglobulin G glycosylation and cancer: A potential glycobiomarker for early tumor detection

Serum IgG N-glycans Enable Early Detection and Early Relapse Prediction of Colorectal Cancer.

The Value of Serum Immunoglobulin G Glycome in the Preoperative Discrimination of Peritoneal Metastasis from Advanced Gastric Cancer

[The Significance of Serum IgD Quantitation for Evaluation of Clinical Efficacy in IgD Multiple Myeloma].

Glycosylation status of serum immunoglobulin G in patients with prostate diseases

Serum Immunoglobulin G N-glycome: a Potential Biomarker in Endometrial Cancer.

Serum N-Glycome analysis reveals pancreatic cancer disease signatures

Glycomic Signatures of Plasma IgG Improve Preoperative Prediction of the Invasiveness of Small Lung Nodules.

Glyco-signatures in patients with advanced lung cancer during anti-PD-1/PD-L1 immunotherapy

Diagnostic Potential of Plasma IgA1 O-Glycans in Discriminating IgA Nephropathy From Other Glomerular Diseases and Healthy Participants

Analysis of Serum IgG1 to Predict Progression and Therapeutic Effect in Patients with Multiple Myeloma

Prediction of Neoadjuvant Chemotherapeutic Efficacy in Patients with Locally Advanced Gastric Cancer by Serum IgG Glycomics Profiling.

N-linked glycosylation of the M-protein variable region: glycoproteogenomics reveals a new layer of personalized complexity in multiple myeloma

Cell Surface-Specific N-glycan Profiling in Breast Cancer.

A serum glycomics approach to breast cancer biomarkers

Use of the serum glycan state to predict ovarian cancer patients' clinical response to chemotherapy treatment.